


Half-Year Report

from the
01st of January
to the
30th of June 2015



Letter to Our Stockholders

Dear Stockholders:

We are very pleased to be able to report about the very positive development of our business and decisive future-oriented strategic steps in the first half by 2015! Against the background of the strong figures of the previous year and substantial integration costs due to recent acquisitions, this development is particularly gratifying.

With increased sales of approx. 24 % and a higher result before taxes and interest of about 20 %, the NEXUS team has again been able to continue our growth course connected with continual improvement of our results in the first half year 2015. In addition to the strong development of sales and results, we started the strategy projects „Entry into the Dutch market“ and „Reorganization of the NEXUS-Group“ at the same time in the first half year.

We were able to acquire a strong company in the Dutch market with quCare B.V., Utrecht. We see considerable synergy potential in the collaboration: The company – which is now trading under the name of NEXUS Nederland – will become a complete provider of e-health solutions in the Netherlands thanks to the extension of the product range and the integration of NEXUS software modules. We will be able to offer administrative, clinical and diagnostic solutions from one source in the future. We expect substantial stimuli from the acquisition in the internationalization of our business, but also significant synergy effects on product levels.

With the expansion of our business to another strategic market, NEXUS is increasingly operating as a European company. We have development and sales locations in Germany, Switzerland, Austria, France and the Netherlands in the meantime. We are pursuing the goal of sharing expertise, software and procedures between markets intensively and adopting the „best practices“ from the respective health systems. To pursue this objective even more intensively and to ensure that a comprehensive view of the product is maintained in addition to the local concentration, we reorganized our activities in the second quarter. The core of the reorganization is the establishment of subsidiaries in key markets. We are convinced that we can generate more growth with this transparent and result-responsible structure for our business.

These organizational changes fit very well with our basic product innovations, which we will launch on the market this year:

1. We are implementing an entirely new user interface within our products and thereby are defining a new way of using clinical software products. In place of screens overloaded with functions, our screen layouts now only focus on the essential in a work situation. We call this kind of interface design „dynamic workspaces“.
2. We are expanding our mobility concept „NEXUS / MOBILE“ considerably and consequently designing the application of NEXUS / HIS to be increasing mobile.
3. The automated and intelligent support of diagnostic processes within our product group „NEXUS / SPECIAL DIAGNOSTICS“ represents the third focus of our development activities.

We ascribe great importance to all of these three product innovations in creating economic efficiency in hospitals and acceptance of the users.

1st Half-Year Highlights – 2015 – Company Development

- + Very strong development of sales in the first half-year
- + Acquisition of a Dutch KIS provider
- + Acquisitions and currency rate-related special factors in the first half-year
- + Reorganization of the NEXUS group into subsidiaries

Our strong focus on innovation sets an important signal in the market at the same time. NEXUS does not focus on market consolidation, but instead relies completely on the development and improvement of its product position. There is still substantial potential for hospitals, rehabilitation and care facilities with the introduction of e-health solutions, and we are convinced that the market will grow in the future.

That can also be seen in new projects in 2015: We were able to win new orders for total hospital solutions in Germany, Netherlands, France and Austria. We also received numbers orders in the diagnostic field, in particular in the areas of radiology (the new NEXUS / RIS) and cardiology (CWD).

It is especially good news that Olympus Europe announced collaboration with NEXUS in the field of endoscopic documentation in August. In the technology partnership, the existing endoscopic software of the market leader Olympus will be developed jointly by NEXUS and Olympus in the future. The cooperation is Europe-wide and will give a further boost to our internationalization. Although preliminary investments were considerable over the last few months, we expect not only attractive sales but also strong substantive synergies with the endoscopy and OP specialists Olympus from this cooperation in the future.

Dear Shareholders, the first six months were demanding and have shown a number of changes in the structure and in the business structure of the NEXUS. We are very pleased with the success of our product innovations and are pleased that the integration of new businesses in the NEXUS has been positive for the most part. However, we must not overlook the challenges and risks that are in our rapidly evolving business model. We are still faced with a great challenge in developing the NEXUS in its internationalized structure into the leading European provider of e-health solutions.

We are committed to this goal and look forward to the challenges associated with it. We want to thank you, dear Shareholders, for your trust.

Warm regards,



Dr. Ingo Behrendt
CEO



Financial Highlights

for the 1st Half-Year 2015 and 2014

	30/06/2015	30/06/2014	Changes
	KEUR	KEUR	%
Sales	47,051	37,823	24.4
Healthcare Software Sales	43,454	33,602	29.3
Healthcare Service Sales	3,597	4,221	-14.8
Domestic Sales	23,264	22,376	4.0
Sales in foreign countries	23,787	15,447	54.0
Group result before interests and tax on income (EBIT)	4,284	3,581	19.6
Group result before interests	4,350	3,662	18.8
Consolidated Surplus	4,395	3,622	21.3
EBITA	8,295	4,441	86.8
EBITDA	8,923	6,898	29.4
Earnings per Share	0.28	0.25	12.0
Depreciation	4,639	3,317	39.9
Net Liquidity	20,529	24,911	-17.6
Cash Flow from current business transactions	10,924	5,064	115.7
Employees (as of the record date)	807	650	24.2

Interim Annual Report

Report about the Profit, Financial and Asset Situation

NEXUS Group sales increased from KEUR 37,823 to KEUR 47,051 (+24.4 %) in the first six months of the year 2015.

As a result, the sustained steady sales development of the NEXUS Group of recent years could be continued in the first half of 2015. The decisive growth impulses came from the area of Healthcare Software. Sales in this segment increased from KEUR 33,602 to KEUR 43,454 (+29.3 %). The Healthcare Service Division was able to achieve revenues of KEUR 3,597 compared to the first half of 2014 with KEUR 4,221 (-14.8 %).

We were able to increase sales in Germany by 4.0 % to KEUR 23,264 (1st HY 2014: KEUR 22,376). In international business, we recorded sales of KEUR 23,787 in the first half-year compared to KEUR 15,447 in the previous year (+54.0 %). The increase is due decisively to initial consolidation of NEXUS Nederland for the months February to June. We also had a significant revenue increase in France, where we consolidated our subsidiary CS3I, Vichy. There were sales effects from exchange rate fluctuations of the Swiss franc in the amount of KEUR 1,785. The average exchange rate of the Swiss franc of SFR 1.06 on 30 June 2015 was below of the average price on 31 Dec. 2014 (SFR 1.21).


The operating result before taxes and interest (EBIT) improved by 19.6 % to KEUR 4,284 (1st HY 2014: KEUR 3,581). EBITA rose very significantly. We reached a value of KEUR 8,295 there and were 86.8 % above the value of previous year (1st HY 2014: KEUR 4,441) as a result. EBITDA also developed very positively. We achieved KEUR 8,923 in the first six months of the year 2015 and thus an increase of 29.4 % compared to the first half of the previous year (KEUR 6,898).

The cash flow from current business transactions developed even better. With an increase of 115.7 % to KEUR 10,924, the cash flow was KEUR 5,860 higher than the already high figure of the previous year (1st HY 2014: KEUR 5,064). The reasons for this are the higher business volume and active accounts receivable management.


The consolidated surplus amounted to KEUR 4,395 for the first half-year 2015 following KEUR 3,622 (1st HY 2014) and consequently increased by approx. 21.3 %. Earnings per share also evolved upwards and amounted to EUR 0.28 (1st HY 2014: EUR 0.25).

Cash and cash equivalents including securities amounted to KEUR 20,529 on 30 June 2015 (31 Dec. 2014: KEUR 22,578).

Group sales (6 months) in KEUR
+24.4 % as of previous year



Profit before interest and tax (6 months) in KEUR
+19.6 % as of previous year



Investments in tangible and intangible assets were made in the amount of KEUR 4,069 in the first half-year (1st HY 2014: KEUR 3,199). This includes KEUR 1,300 for the acquisition of land and buildings. NEXUS is investing in a new headquarters, which we expect to move into at the beginning of 2016.

A total of KEUR 18,064 was invested in the first half-year for the acquisition of the quCare Group, Utrecht, Netherlands, and for payment of residual purchase price claims from previous acquisitions after deduction of cash acquired.

The balance sheet total increased from KEUR 108,189 to KEUR 135,514 compared to 31 December 2014. There are no essential bank liabilities. Intangible assets, goodwill and balanced-out deferred taxes add up to a total of KEUR 76,566 following KEUR 57,283 (31 Dec. 2014). Receivables from customers increased from KEUR 19,275 to KEUR 22,468 compared to 31 December 2014.

Capital

The Executive Board of NEXUS AG decided on 26 February 2015 on a capital increase with the consent of the Supervisory Board for partial refinancing of acquisitions made over the past few months. Using the authorized capital available, the capital stock of NEXUS AG was increased by EUR 630,515 (4.2 %) from the previous EUR 15,105,150 to EUR 15,735,665 against cash investment via issue of 630,515 registered shares with exclusion of subscription rights. Thanks to the placement of new shares among investors, 8.8 million euros gross were taken in. The issue price was 13.95 euros. By resolution of the general stockholders meeting on 18 May 2015 NEXUS paid a dividend of EUR 0.13 per share for the business year 2014.

Financial 1st Half-Year Highlights – 2015

- + 24.4 % sales increase from KEUR 37,823 (1st HY 2014) to KEUR 47,051 in the first half-year 2015
- + 21.3 % increase of the consolidated surplus from KEUR 3,622 (1st HY 2014) to KEUR 4,395
- + Increase in EBITDA of 29.4 % to KEUR 8,923 (1st HY 2014: KEUR 6,898)
- + Strongly positive operative cash flow (+115.7 %) KEUR 10,924 following KEUR 5,064

Employees

NEXUS Group employed a total of 807 people as of 30 June 2015 (Q2 2014: 650 employees). A total of 752 employees (Q2 2014: 583) are employed in the Healthcare Software Division. The Healthcare Service Division employed 55 people (Q2 2014: 67).

Sales by division

	01/01/ - 30/06/15	01/01/ - 30/06/14	Changes	01/04/ - 30/06/15	01/04/ - 30/06/14	Changes
	KEUR	KEUR	%	KEUR	KEUR	%
Healthcare Software	43,454	33,602	29.3	22,295	16,950	31.5
Healthcare Service	3,597	4,221	-14.8	1,989	2,277	-12.6
Total	47,051	37,823	24.4	24,284	19,227	26.3

Sales by region

	01/01/ - 30/06/15	01/01/ - 30/06/14	Changes	01/04/ - 30/06/15	01/04/ - 30/06/14	Changes
	KEUR	KEUR	%	KEUR	KEUR	%
Germany	23,264	22,376	4.0	12,249	12,322	-0.6
Switzerland	12,788	12,490	2.4	6,187	5,748	7.6
Netherlands	6,776	0	-	3,769	0	-
France	2,710	1,140	> 100	1,420	488	> 100
Austria	934	877	6.5	361	366	-1.4
Other countries	579	940	-38.4	298	303	-1.7
Total	47,051	37,823	24.4	24,284	19,227	26.3



**NEXUS / NEXT GENERATION:
A personal workspace:
adapts to your work steps!**

We are introducing a fundamental new operating concept in NEXUS / HIS with the NEXT GENERATION software from NEXUS: faster use through interfaces that adapt to individual worker processes.



**NEXUS / NEXT GENERATION:
A personal workspace:
adapts to your work steps!**

We are introducing a fundamental new operating concept in NEXUS / HIS with the NEXT GENERATION software from NEXUS: faster use through interfaces that adapt to individual worker processes.

NEXUS Group Information and Outlook

Chances and Risks Report

Please refer to the explanations in the annual report of 31 December 2014 for information about the essential chances and risks in the development of NEXUS Group. There have been no essential changes in the meantime.

Outlook: Develop in a Targeted Manner

The first half of 2015 has confirmed the uninterrupted positive trend of recent years again. Sales rose by approx. 24 %, earnings before taxes by approx. 20 % and the operating cash flow reached approx. € 11 million after € 5 million in the first half of last year. The initial consolidation of NEXUS Nederland (Netherlands) sales for five months and the favorable development for NEXUS of the exchange rate of the Swiss franc helped to achieve this impressive development.

With these results, we are again increasing our targets and confirming that we want to position ourselves as a strong European e-health company. We see this positioning significant opportunities for further growth and are convinced that the exchange of products, knowledge and technology between the European countries is a promising way to combine product innovation and profitability. We have an excellent technology base, a broad product range and a large number of existing customers to achieve this goal. We will have to prove in the second half-year that we can continue to improve and expand this starting situation as well as our extraordinary development.

Directors' Holdings

The director's holders of the Supervisory Board and the Executive Board are as follows on 30 June 2015 in comparison to the previous year: cf. Table.

Supervisory Board	Numbers of stock owned	Numbers of options
Dr. jur. Hans-Joachim König	89,900 Previous year (101,239)	0 Previous year (0)
Prof. Dr. Alexander Pocsay	121,500 Previous year (121,500)	0 Previous year (0)
Gerald Glasauer	0 Previous year (-)	0 Previous year (-)
Prof. Dr. Ulrich Krystek	0 Previous year (0)	0 Previous year (0)
Wolfgang Dörflinger	0 Previous year (0)	0 Previous year (0)
Prof. Dr. med. Felicia M. Rosenthal	0 Previous year (-)	0 Previous year (-)

Executive Board	Numbers of stock owned	Numbers of options
Dr. Ingo Behrendt	112,000 Previous year (112,000)	0 Previous year (0)
Ralf Heilig	135,350 Previous year (135,350)	0 Previous year (0)
Edgar Kuner	248,051 Previous year (248,051)	0 Previous year (0)

Capital market, event and finance data

Investor Relations

Active communication with our stockholders, potential investors, analysts and the finance market are the focal point of our investor relation activities. We continually inform all market participants promptly and comprehensively via press releases and ad hoc announcements as well as the mandatory quarterly, semi-annual and annual financial reports.

In addition, we cultivate intensive dialog with institutional investors and finance analysts via telephone conferences, one-on-one meetings and on roadshows. Our Investor Relations team is of course at your disposal as contact persons.

Frankfurt Stock Exchange stock prices (1-year period)



Stock Market Highlights (XETRA closing prices)

- + Initial listing on 2 January 2015: € 11,87
- + Highest price on 18 May 2015: € 18,10
- + Stock Market Price on 30 June 2015: € 16,65
- + Stock market capitalization on 30 June 2015: € 262,0 million

18/09 - 19/09/2015

15. Jahrestagung der AAL, Essen

23/09 - 26/09/2015

VKD Tagung, Sellin

24/09 - 25/09/2015

KH-IT Herbsttagung, Düsseldorf

04/10 - 06/10/2015

DGSV Kongress 2015, Fulda

16/10 - 17/10/2015

KTQ-Forum, Berlin

26/11 - 29/11/2015

Fortbildungstagung Klinische Zytologie, Munich

01/12 - 03/12/2015

27. Deutscher Kongress für Perinatale Medizin, Berlin

02/12 - 04/12/2015

DIVI-Kongress für Intensiv- und Notfallmedizin, Leipzig

18 August 2015

Half Year Report 2015

10 November 2015

Quarterly Report Q3-2015

23 - 25 November 2015

German Equity Forum, Frankfurt

Consolidated Profit and Loss Account as of 30/06/2015 and 30/06/2014

	01/01- 30/06/2015	01/01- 30/06/2014	01/04- 30/06/2015	01/04- 30/06/2014
	KEUR	KEUR	KEUR	KEUR
Revenue	47,051	37,823	24,284	19,228
Development work capitalized	2,397	2,099	1,081	861
Other operating income	1,362	554	401	414
Cost of materials including purchased services	7,196	6,958	3,461	3,440
Personnel costs	27,754	21,293	14,175	10,706
Depreciation	4,639	3,317	2,434	1,669
Other operating expenses	6,936	5,237	3,537	2,919
Operating Result	4,284	3,581	2,158	1,769
Finance Income	78	104	57	36
Finance Expenses	12	23	3	20
Result before Tax on Profit	4,350	3,662	2,212	1,785
Taxes on profit	-46	40	-97	-32
Consolidated Surplus	4,395	3,622	2,308	1,817
of the consolidated surplus, accounted to:				
- Stockholders of NEXUS AG	4,427	3,796	2,300	2,011
- Shares of non-controlling partners	-32	-174	8	-194
Consolidated surplus per share in EUR				
Weighted average of issued shares in circulation (in thousands)	15,610	15,069	15,610	15,069
- Simple	0.28	0.25	0.15	0.13
- Diluted	0.28	0.25	0.15	0.13

Consolidated Income Statement as of 30/06/2015 and 30/06/2014

	01/01- 30/06/2015	01/01- 30/06/2014	01/04- 30/06/2015	01/04- 30/06/2014
	KEUR	KEUR	KEUR	KEUR
Consolidated Surplus	4,395	3,622	2,308	1,817
Actuarial profits and losses (after taxes on profit)	-674	0	-25	-5
Tax effects	96	0	3	0
Differences from the conversion of foreign currency (after taxes on profit)	2,485	140	-3	-39
Other Overall Result	1,907	140	-25	-44
Overall Result of the Period	6,302	3,762	2,283	1,773
of the overall result of period, accounted to:				
- Stockholders of NEXUS AG	6,334	3,936	2,275	1,772
- Shares of non-controlling partners	-32	-174	8	1

Consolidated Balance Sheet

as of 30/06/2015 and 31/12/2014

Assets	30/06/2015	31/12/2014
	KEUR	KEUR
Long-Term Assets		
Goodwill	38,728	27,976
Other intangible assets	39,027	27,996
Fixed assets	4,179	2,241
Shares in companies valued at equity	30	34
Diferred tax assets	4,928	4,828
Other financial assets	236	400
Total of Long-Term Assets	87,128	63,475
Short-Term Assets		
Inventories	797	589
Trade receivables and other receivables	22,468	19,275
Receivables from tax on profits	1,198	675
Other non-financial assets	2,855	1,029
Other financial assets	539	568
Short-term financial assets	3,218	9,218
Cash and balance in bank	17,311	13,360
Total of Short-Term Assets	48,386	44,714
Total Assets	135,514	108,189

Equity and Liabilities	30/06/2015	31/12/2014
	KEUR	KEUR
Equity Capital		
Authorized capital	15,736	15,105
Capital reserves	34,009	25,980
Profit carried forward	37,034	30,705
Consolidated surplus	4,427	8,279
Other cumulated Group result	-1,166	-3,074
Own shares	-273	-280
Equity Capital Attributable to Stockholders of the Parent Company	89,767	76,715
Shares of non-controlling partners	-976	-903
Total Equity Capital	88,791	75,812
Long-Term debts		
Pension obligations	8,284	5,987
Deferred tax liabilities	6,117	3,517
Financial liabilities	0	15
Other financial debts	1,270	2,288
Total of Long-Term Debts	15,671	11,807
Short-Term Debts		
Accruals	1,148	1,291
Financial liabilities	15	253
Trade accounts payable	4,425	4,890
Liabilities from tax on profit	1,722	996
Deferred revenue	14,180	985
Other non-financial debts	5,610	4,991
Other financial debts	3,952	7,164
Total of Short-Term Debts	31,052	20,570
Balance Sheet Total	135,514	108,189

Consolidated Cash Flow Statement

for the period from 01/01/ to 30/06/2015 and 2014

	2015	2014
	KEUR	KEUR
1. Cash flow from business operations		
Group result before tax on income	4,350	3,662
Depreciation and amortization of intangible assets and plant, equipment and other fixed assets	4,639	3,317
Other expenses / income with no impact on cash	0	139
Increase / decrease in inventories	-208	-160
Increase / decrease in trade receivables and other assets that cannot be allocated to investing or financing activities	1,580	1,197
Increase / decrease of accruals insofar as not entered in other comprehensive income	-143	-261
Increase / decrease in liabilities from trade receivables as well as other liabilities, that cannot be allocated to investing or financing activities	999	-2,740
Paid interest	-12	-23
Received interest	44	119
Income taxes paid	-534	-217
Income taxes received	209	31
	10,924	5,064
2. Cash Flow from Investment Activities		
Cash paid for investments in intangible and fixed assets	-4,069	-3,199
Purchase of companies after deduction of acquired payment means	-13,995	0
Payments made/received due to investment of funds within the context of short-term fund management	6,000	0
	-12,064	-3,199
3. Cash Flow from Financing Activities		
Capital increase via issue of new shares	8,597	0
Dividend payout	-1,961	-1,808
Share purchase of already completely consolidated companies	-3,087	0
Sale of own shares	52	6
	3,601	-1,802
4. Cash and cash equivalents at end of period		
Cash relevant changes in cash and cash equivalents (sum of 1 + 2 + 3)	2,461	63
Change in currency conversion adjustment	1,743	0
Cash and cash equivalents at beginning of fiscal year	13,107	15,467
	17,311	15,530
5. Composition of cash and cash equivalents		
Liquid Funds	17,311	15,769
Bank liabilities due on demand	0	-239
	17,311	15,530

Statement of Changes in Consolidated Equity

as of 30/06/2015 and 30/06/2014

	Subscribed capital	Capital reserves	Equity capital difference from currency conversion	Pensions provisions	Profit carried forward	Annual Net Profit	Own Shares	Equity capital attributable to stock of parent company	Shares of non-controlling partners	Equity Capital total	Authorized Capital
	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR
Consolidated Equity as of 01/01/2014	15,105	25,780	504	-1,592	25,293	7,221	-290	72,021	-526	71,495	6,353
Posting of the consolidated profit 2013 in the Group profit carried forward					7,221	-7,221		0		0	
Total of the result entered directly into equity capital			140					140		140	
Other Comprehensive Income After Taxes 30/06/2014	0	0	140	0	7,221	-7,221	0	140	0	140	0
Consolidated surplus 1. HY-2014						3,796		3,796	-174	3,622	
Overall Result of the Period	0	0	140	0	7,221	-3,425	0	3,936	-174	3,762	0
Dividend payment					-1.808			-1.808		-1.808	
Purchase/sale of own shares		5					1	6		6	
Consolidated Equity as of 30/06/2014	15,105	25,785	644	-1,592	30,706	3,796	-289	74,155	-700	73,455	6,353
Consolidated Equity as of 01/01/2015	15,105	25,980	897	-3,971	30,705	8,279	-280	76,715	-903	75,812	6,353
Posting of consolidated surplus 2014 in the Group loss carried forward					8,279	-8,279		0		0	
Actuarial profits and losses				-673				-673		-673	
Deferred taxes entered in other comprehensive income				96				96		96	
Currency exchange differences			2,485		11			2,496	-41	2,455	
Other Comprehensive Income After Taxes 30/06/2015	0	0	2,485	-577	8,290	-8,279	0	1,919	-41	1,878	0
Consolidated surplus 1. HY-2015						4,427		4,427	-32	4,395	
Overall Result of the Period	0	0	2,485	-577	8,290	-3,852	0	6,346	-73	6,273	0
Dividend payment					-1,961			-1,961		-1,961	
Purchase/sale of own shares		45					7	52		52	
Capital Increase	631	7,966						8,597		8,597	-631
Change in capital reserves		18						18		18	
Consolidated Equity as of 30/06/2015	15,736	34,009	3,382	-4,548	37,034	4,427	-273	89,767	-976	88,791	5,722

Appendix

to the Consolidated Interim Financial Report

1. Accounting and Valuation Methods

This interim report from the NEXUS Group of 30 June 2015 has been prepared in keeping with the International Financial Reporting Standards (IFRS) as they are applied in the EU. The interpretations of the International Financial Reporting Interpretation Committee (IFRIC) have been taken into account.

The regulations of IAS 34 were observed in the interim report of 30 June 2015. This refers to a summarized report, which does not contain all information of an IFRS Group Financial Statement, and consequently this report should be read in connection with the Appendix of the Group Financial Statement 2014. The same accounting and valuation methods were used in the Group Financial Statement for the business year 2014.

The report has not been audited.

The Annual Report 2014 and Half-Year Report as of 30 June 2015 could be downloaded on www.nexus-ag.de.

2. Consolidation Group

In addition to the NEXUS AG as parent company, all operatively active domestic and foreign subsidiaries are included in the Group Financial Statement, for which NEXUS AG has the majority of voting rights directly or indirectly.

Three affiliated companies were included in the balance sheets according to the equity method.

List of consolidated subsidiaries and affiliated companies

		30/06/2015	31/12/2014
	Country	Capital share in %	Capital share in %
Full consolidation			
NEXUS Digitale Dokumentationssysteme Projektentwicklungsges.m.b.H., Wien	Austria	100.00	100.00
NEXUS / IS GmbH, Villingen-Schwenningen	Germany	100.00	100.00
NEXUS . IT GmbH SÜDOST, Singen Hohentwiel	Germany	50.20	50.20
nexus/cms GmbH (formerly: NEXUS . IT GmbH NORD), Villingen-Schwenningen	Germany	100.00	100.00
NEXUS Medizinsoftware und Systeme AG, Altishofen	Switzerland	99.98	99.98
syseca informatik ag, Luzern	Switzerland	100.00	100.00
NEXUS / INOVIT GmbH, Ismaning	Germany	100.00	100.00
NEXUS / CIS GmbH, Singen Hohentwiel	Germany	100.00	100.00
NEXUS / DIS GmbH, Frankfurt am Main	Germany	100.00	100.00
NEXUS Schweiz GmbH, Schwerzenbach ¹⁾	Switzerland	100.00	100.00
NEXUS / QM GmbH, Ismaning	Germany	100.00	100.00
NEXUS / REHA GmbH, Villingen-Schwenningen	Germany	100.00	100.00
Flexreport AG, Wallisellen	Switzerland	100.00	100.00
NEXUS / CSO GmbH, Villingen-Schwenningen	Germany	100.00	100.00
VEGA Software GmbH, Aachen	Germany	60.00	60.00
Domis Consulting AG, Altishofen	Switzerland	100.00	100.00
Synergetics AG, Altishofen ²⁾	Switzerland	60.00	60.00
NEXUS / OPTIM S.A.S, Grenoble	France	100.00	100.00

List of consolidated subsidiaries and affiliated companies

		30/06/2015	31/12/2014
	Country	Capital share in %	Capital share in %
Full consolidation			
E&L medical systems GmbH, Erlangen	Germany	100.00	100.00
ASS.TEC Beratungsgesellschaft für Anwendungen, Systeme, Strategien und Technologien mbH, Villingen-Schwenningen	Germany	100.00	100.00
proLohn GmbH, Singen	Germany	51.00	51.00
Marabu EDV-Beratung und -Service GmbH, Berlin ³⁾	Germany	100.00	100.00
CS3I S.A.S., Creuzier-le-Neuf	France	100.00	100.00
NEXUS Nederland B.V. (formerly: quCare Solutions B.V.), Nieuwegein	Netherlands	100.00	-
Equity consolidation			
G.I.T.S. Gesundheitswesen IT-Service GmbH Fürstenfeldbruck, Fürstenfeldbruck	Germany	49.00	49.00
Medidata GmbH, Berlin	Germany	25.00	25.00
Palladium-med GmbH, Berlin	Germany	20.00	20.00

1) The shares are held indirectly via NEXUS Medizinsoftware und Systeme AG, Altshofen.

2) The shares are held indirectly via Domis Consulting AG, Altshofen.

3) Share under company law is only 93 %. There are forward and option contracts for the remaining 7 %.

3. Trade account receivables and other assets

In KEUR	30/06/2015		31/12/2014		30/06/2014	
	short-term (< 1 year)	long-term (> 1 year)	short-term (< 1 year)	long-term (> 1 year)	short-term (< 1 year)	long-term (> 1 year)
Requirements						
Trade receivables	22,246	0	19,165	0	16,133	0
Receivables from companies valued at equity	18	0	18	0	12	0
Other receivables	204	0	92	0	147	0
Total receivables	22,468	0	19,275	0	16,292	0
Other financial assets						
From interest not due yet	4	0	4	0	7	0
From loans to employees and third parties	19	0	74	20	82	23
From other	516	236	490	380	2,527	65
Total of other financial assets	539	236	568	400	2,616	88
Income tax assets	1,198	0	675	0	764	0

The other assets are not interest-bearing and normally are due between 30 and 360 days. Loans to third parties have interest rates of 3.5 % and 5 % and are normally safeguarded. Trade receivables are not interest-bearing and normally are due between 30 and 90 days.

There were receivables from deliveries and services in the amount of KEUR 1,094 on 30 June 2015 (30 June 2014: KEUR 1,287) diminished in value. The development of the value adjustment account is as follows:

Allowance account	30/06/2015	31/12/2014	30/06/2014
	KEUR	KEUR	KEUR
As of 1 January	1,402	1,559	1,559
Inflows affecting expenses	57	512	134
Consumption	-105	-465	-278
Settlement	-260	-204	-128
Amounts at end of the period	1,094	1,402	1,287

4. Securities

In KEUR	30/06/2015		31/12/2014		30/06/2014	
	acquisition costs	market value	acquisition costs	market value	acquisition costs	market value
Money market loans	2,014	1,823	2,014	1,823	2,014	1,750
Funds shares	719	395	719	395	719	392
Total	2,733	2,218	2,733	2,218	2,733	2,142

5. Liabilities

In KEUR	30/06/2015		31/12/2014		30/06/2014	
	short-term (< 1 year)	long-term (> 1 year)	short-term (< 1 year)	long-term (> 1 year)	short-term (< 1 year)	long-term (> 1 year)
Financial liabilities	15	0	253	15	201	38
Trade accounts payable	4,425	0	4,890	0	3,302	0
Profit tax liabilities	1,722	0	996	0	454	0
Deferred revenue	14,180	0	985	0	6,127	0
Other non-financial debts	5,610	0	4,991	0	4,096	0
- Payments received	2,663	0	2,178	0	1,958	0
- Other taxes	2,947	0	2,813	0	2,138	0
Other financial debts	3,952	1,270	7,164	2,288	3,084	2,586
- From obligations for salary payables	2,014	0	1,347	0	2,565	0
- Other	1,938	1,270	5,817	2,288	519	2,586
Summe	29,904	1,270	19,279	2,303	17,264	2,624

Conditions of the financial liabilities listed above:

- + Liabilities to banks serve solely for short-time payments. Interest due here is paid monthly.
- + Average down payments on orders are offset after 12 months.
- + Liabilities from deliveries and services are not interest-bearing and normally are due with 30 days.

6. Segment reporting

Reporting by business segment as of 30 June	Healthcare Software		Healthcare Service		Consolidation		Group	
	2015	2014	2015	2014	2015	2014	2015	2014
	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR
Sales with third parties	43,454	33,602	3,597	4,221			47,051	37,823
- Services	33,552	25,393	3,002	2,810			36,554	28,203
- Licenses	7,668	6,195	288	773			7,956	6,968
- Deliveries	2,234	2,014	307	638			2,541	2,652
Sales between segments	0	19	850	1,513	-850	-1,532	0	0
Segment sales	43,454	33,621	4,447	5,734	-850	-1,532	47,051	37,823
Operating segment result	3,778	3,129	506	452			4,284	3,581
Segment assets	105,001	73,723	3,416	3,415			108,417	77,138

Segmenting according Business Divisions

The Group is split into business units according to products and services for the purpose of company management and has the following business segments required to file reports:

Healthcare Software

In the business units NEXUS / CIS, NEXUS / CSO, NEXUS / DIS, NEXUS / HOSPIS, NEXUS / HOME and Domis (both Switzerland) as well as NEXUS / OPTIM and CS3I (both France) as well as NEXUS Nederland, software solutions for the healthcare system are developed and marketed in administrative and medical areas. NEXUS provides a hospital information system (HIS) with its core product NEXUS / HIS for the medical sector. The counterpart products NEXUS / PSYCHIATRY and NEXUS / REHA are offered respectively for psychosomatic institutions and rehabilitation institutions. We provide all administration applications for the Swiss market with the product line NEXUS / HOSPIS. We offer the same range of applications under the brand name xCare to the Dutch market.

Highly specialized solutions are available (NEXUS / DIS) for radiology, gynecology including obstetrics, pathology and cytology. The leading system for QM certification of all customary processes (NEXUS / ZERT) has also been assigned to this area. NEXUS also expanded its portfolio for quality management software with the product NEXUS / CURATOR. All further existing departments, like endoscopy, cardiology and oncology are served with the product range of E & L Medical Systems GmbH, Erlangen.

Healthcare Service

The Healthcare Service Division covers the services, which are provided by NEXUS . IT GmbH SÜDOST, nexus/cms GmbH and ASS.TEC GmbH, Villingen-Schwenningen as well as proLohn GmbH. These including consulting for hospital IT departments, process consulting, SAP introduction, SAP HR consulting, configuration of network, Intranet and Internet solutions, security concepts and the management of IT services.

NEXUS Group is mainly controlled according to business divisions due to the chance and risk structure. Consequently, the division according to business divisions is the primary segmentation level. Transactions between the segments are mainly debited as procurement or manufacturing costs.

7. Seasonal Influences on Business Transactions

Within the context of the operative business of NEXUS Group, seasonal effects result due to the receipt of maintenance revenues in the first quarter of the business year (the revenue influences of the corresponding received payments are accrued over the business year) as well as the substantially higher demand and settlement of project accounts in the fourth quarter of the business year.

Declaration according to § 37y No. 1 WpHG

To the best of our knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim consolidated financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the group, and the interim management report of the group includes a fair review of the development and performance of the business and the position of the group, together with a description of the principal opportunities and risks associated with the expected development of the group for the remaining months of the financial year.

Villingen-Schwenningen, 18 August 2015

NEXUS AG
The Executive Board

nexus/ag

NEXUS AG, Auf der Steig 6, D-78052 Villingen-Schwenningen
Telefon +49 (0)7721 8482 -0, Fax +49 (0)7721 8482-888
www.nexus-ag.de, info@nexus-ag.de